Imatinib Mesylate (Gleevec) and Paclitaxel in Recurrent Patients of Ovarian and Other Cancers of Mullerian Origin

Summary

This study is designed to determine whether the combination treatment of Paclitaxel and Gleevec on recurrent ovarian cancer patients or other cancers of mullerian origin will generate better clinical response than Paclitaxel alone.

Timeline

Start

2007-04

Primary completion

2010-04

Completion

2012-10

Outcome

Outcome not reported

Stopped (Enrollment): “Due to slow accrual”

Drugs

Indications